LLY

1,037.33

-1.17%↓

JNJ

205.1

+0.61%↑

ABBV

229.53

+2.76%↑

UNH

339.22

+4.86%↑

AZN

90.75

+0.63%↑

LLY

1,037.33

-1.17%↓

JNJ

205.1

+0.61%↑

ABBV

229.53

+2.76%↑

UNH

339.22

+4.86%↑

AZN

90.75

+0.63%↑

LLY

1,037.33

-1.17%↓

JNJ

205.1

+0.61%↑

ABBV

229.53

+2.76%↑

UNH

339.22

+4.86%↑

AZN

90.75

+0.63%↑

LLY

1,037.33

-1.17%↓

JNJ

205.1

+0.61%↑

ABBV

229.53

+2.76%↑

UNH

339.22

+4.86%↑

AZN

90.75

+0.63%↑

LLY

1,037.33

-1.17%↓

JNJ

205.1

+0.61%↑

ABBV

229.53

+2.76%↑

UNH

339.22

+4.86%↑

AZN

90.75

+0.63%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

44.49 3.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.68

Max

44.59

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+27.76% upside

Turustatistika
By TradingEconomics
Turukapital	132M 3.4B
Eelmine avamishind	41.05
Eelmine sulgemishind	44.49

Uudiste sentiment

By Acuity

50%

162 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. dets 2025, 17:29 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2. dets 2025, 16:21 UTC

Tulu

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2. dets 2025, 16:18 UTC

Tulu

Correction to Scotiabank Quarterly Earnings Buoyed Article

2. dets 2025, 23:53 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

2. dets 2025, 22:48 UTC

Tulu

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2. dets 2025, 22:12 UTC

Market Talk

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2. dets 2025, 22:03 UTC

Market Talk

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2. dets 2025, 22:00 UTC

Market Talk

Global Equities Roundup: Market Talk

2. dets 2025, 22:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. dets 2025, 22:00 UTC

Market Talk

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2. dets 2025, 21:56 UTC

Tulu

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. dets 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. dets 2025, 21:44 UTC

Tulu

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. dets 2025, 21:38 UTC

Market Talk

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2. dets 2025, 21:19 UTC

Tulu

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. dets 2025, 20:06 UTC

Market Talk

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2. dets 2025, 19:55 UTC

Market Talk

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2. dets 2025, 19:53 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

2. dets 2025, 19:53 UTC

Market Talk

Tulu

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2. dets 2025, 19:24 UTC

Market Talk

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2. dets 2025, 19:06 UTC

Market Talk

Precious Metals Step Back After Silver Sets Record -- Market Talk

2. dets 2025, 18:27 UTC

Omandamised, ülevõtmised, äriostud

Kraken to Acquire Backed Finance AG

2. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. dets 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. dets 2025, 15:17 UTC

Market Talk

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2. dets 2025, 14:47 UTC

Market Talk

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2. dets 2025, 14:38 UTC

Market Talk

Silver Steps Back From Record Levels -- Market Talk

2. dets 2025, 14:31 UTC

Market Talk

Tulu

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

27.76% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 27.76%

Kõrge 65 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

162 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.